WO2009002149A1 - Procédé de détermination d'une mutation potentielle - Google Patents

Procédé de détermination d'une mutation potentielle Download PDF

Info

Publication number
WO2009002149A1
WO2009002149A1 PCT/NL2007/050317 NL2007050317W WO2009002149A1 WO 2009002149 A1 WO2009002149 A1 WO 2009002149A1 NL 2007050317 W NL2007050317 W NL 2007050317W WO 2009002149 A1 WO2009002149 A1 WO 2009002149A1
Authority
WO
WIPO (PCT)
Prior art keywords
individual
vibrational
spectrum
nmf
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NL2007/050317
Other languages
English (en)
Inventor
Peter Jacobus Caspers
Hok Bing Thio
Gerwin Jan Puppels
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Erasmus MC
Original Assignee
Erasmus MC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erasmus MC filed Critical Erasmus MC
Priority to PCT/NL2007/050317 priority Critical patent/WO2009002149A1/fr
Priority to US12/666,311 priority patent/US20100322860A1/en
Priority to EP08766842.2A priority patent/EP2175778B1/fr
Priority to JP2010514662A priority patent/JP5451607B2/ja
Priority to PCT/NL2008/050419 priority patent/WO2009002170A1/fr
Publication of WO2009002149A1 publication Critical patent/WO2009002149A1/fr
Anticipated expiration legal-status Critical
Priority to US15/661,273 priority patent/US20170319070A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A61B5/411—Detecting or monitoring allergy or intolerance reactions to an allergenic agent or substance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
    • A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
    • A61B5/445—Evaluating skin irritation or skin trauma, e.g. rash, eczema, wound, bed sore
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4869—Determining body composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
    • A61B2562/02—Details of sensors specially adapted for in-vivo measurements
    • A61B2562/0233—Special features of optical sensors or probes classified in A61B5/00
    • A61B2562/0242—Special features of optical sensors or probes classified in A61B5/00 for varying or adjusting the optical path length in the tissue

Definitions

  • the invention is directed to a method for non-invasive determination of the potential presence of one or more loss-of- function mutation(s) in the gene encoding for filaggrin.
  • Atopic dermatitis is a major problem in dermatology. Estimates for the prevalence of atopic dermatitis in developed countries range between 15 % and 20 %. [Roll et al. Curr. Opin. Allergy Clin. Immunol. 2004, 4(5), 373-378] Atopic dermatitis represents an enormous burden on health care in general.
  • Atopic dermatitis is a common chronic inflammatory skin disease characterized by itchy, inflamed skin. [Roll et al. Curr. Opin. Allergy Clin. Immunol. 2004, 4(5), 373-378 and Stemmler et al. J. Invest. Dermatol. 2007, 127, 722-724] It is also well known that a predisposition for atopic dermatitis impairs the ability of a person to be active in certain professions such as hair- dressing and cookery.
  • the protein filaggrin is of crucial importance for the formation and maintenance of the skin barrier.
  • the protein is necessary in giving the correct macrostructure to the keratin fibrils and it provides the amino acids for the production of the natural moisturising factor (NMF).
  • NMF natural moisturising factor
  • Known methods to determine mutations in the filaggrin gene use specialised genotyping techniques, see for instance US-A-2003/0 124 553. Specific biochemical assays are required to detect the specific mutations in the gene encoding for filaggrin. Genotyping techniques require multiple cycles of PCR (polymerase chain reaction) amplification and sequencing to isolate and amplify the filaggrin-encoding DNA. Each filaggrin mutation is then analysed by a specific genotyping assay. Most of these assays are not commercially available and several laboratories working on the filaggrin gene mutations have developed their own assays. Analysis of 15 variants of the filaggrin mutation is described by Sandilands et al. in Nature Genetics 2006, 38, 337-342.
  • Genotyping methods are expensive and time-consuming and require highly specialised laboratory facilities and personnel. Genotyping methods are unsuitable for population screening purposes. Accordingly, a need exists for a quick and easy-to-use method to screen the population for the potential presence of loss-of- function mutations in the filaggrin gene.
  • NMF natural moisturizing factor
  • the invention is directed to a method for non-invasive determination of the potential presence of one or more loss of function mutation(s) in the gene encoding for filaggrin of an individual comprising
  • the invention is directed to a method which differentiates between a homozygous and a heterozygous loss-of-function mutation in the filaggrin gene of an individual, comprising classifying the loss of function mutation as a function of the natural moisturising factor content. Further, the invention is directed to a method for treating an individual suffering from atopic dermatitis, comprising determining whether the individual has a potential presence of one or more loss of function mutation(s) in the gene encoding for filaggrin, and adjusting the therapy based on the outcome of said determination.
  • Figure 1 is a Raman spectrum of the stratum corneum of the arm of an individual without a filaggrin mutation.
  • the black areas (numbered 1 and 2) indicate Raman bands from NMF.
  • the grey area (number 3) indicates a Raman band from stratum corneum tissue.
  • Figure 2 is a Raman spectrum of the stratum corneum of the arm of an individual with a filaggrin mutation.
  • the black areas (numbered 1 and 2) indicate Raman bands from NMF.
  • the grey area (number 3) indicates a Raman band from stratum corneum tissue.
  • Figure 3 is a Raman spectrum of the stratum corneum, which illustrates one method to determine the NMF content from the vibrational signal.
  • Figure 4 is a Raman spectrum of natural moisturising factor.
  • Figure 5 is a Raman spectrum of human skin.
  • Figure 6 is a skin depth profile of natural moisturising factor of an individual without filaggrin polymorphism.
  • Figure 7 is a skin depth profile of natural moisturising factor of an individual with filaggrin polymorphism.
  • Figure 8 shows the relative natural moisturising factor content in the arm of individuals without filaggrin polymorphism. The dashed line indicates the median NMF content.
  • Figure 9 shows the relative natural moisturising factor content in the arm of individuals with filaggrin polymorphism. The dashed line indicates the median NMF content in the arm of individuals without filaggrin polymorphism.
  • Figure 10 shows the relative natural moisturising factor content in the thenar of individuals without filaggrin polymorphism. The dashed line indicates the median NMF content.
  • Figure 11 shows the relative natural moisturising factor content in the thenar of individuals with filaggrin polymorphism.
  • the dashed line indicates the median NMF content in the thenar of individuals without filaggrin polymorphism.
  • vibrational spectroscopy is defined as any spectroscopic technique that allows the analysis of vibrational and/or rotational modes of a molecule.
  • Radar spectroscopy is defined as a spectroscopic technique used to study vibrational and/or rotational modes in a system, and relies on inelastic scattering (also referred to as Raman scattering) of monochromatic light, usually from a laser in the visible, near infrared, or near ultraviolet range.
  • the incident laser light can lose or gain quanta of vibrational and/or rotational energy from the system, which results in a change of energy of the laser photons. This change in energy of the laser photons causes a spectral shift and provides information on the vibrational and/or rotational modes in the system.
  • a sample is illuminated with a laser beam.
  • Wavelengths close to the laser line are filtered out and those in a certain spectral window away from the laser line are dispersed onto a detector.
  • a Raman spectrum is a set of very narrow spectral lines emitted from object molecules when illuminated by an incident light.
  • the width of each spectral line is strongly affected by the spectral width of the incident light and hence tightly monochromatic light sources, such as lasers, are used.
  • the wavelength of each Raman line is expressed as a wavenumber-shift from the incident light, which is the difference between the wavenumber of the Raman line and the incident light.
  • the wavenumber-shift, not the absolute wavenumber, of the Raman lines is specific to particular atomic groups in molecules.
  • Raman spectra measure the vibrational and/or rotational modes of molecules which are determined by their molecular structure, especially by atomic groups such as methylene, ethylene, amide, phosphate or sulphide.
  • Raman spectroscopy is mainly used for qualitative studies of molecules and molecular dynamics in biology. For easier and clearer interpretation of Raman spectra, use of the technique has been restricted mainly to purified materials and their systems, such as enzyme reactions.
  • Raman spectra are based on the specific vibrations and/or rotations of atomic groups they can also be used to characterise and quantify a mixture of molecules as compositions of atomic groups by a method akin to fingerprinting. Although unable to completely resolve the composition of a sample in terms of a list of chemical compounds, but for the most abundant molecular species, it does give a rough sketch of the molecular composition of the natural environment and how it changes with time.
  • the term "local natural moisturising factor content" as used herein is defined as the NMF content or NMF concentration in the stratum corneum at a given location on the body, such as the volar aspect of the forearm or the thenar (palm of the hand) and at a given distance below the skin surface.
  • the inventors now surprisingly found that, despite the many variations in the NMF concentration or NMF content in the corneum stratum of the skin, a suitable choice of measuring technique allows a reliable diagnosis that an individual has a loss-of-function mutation in the filaggrin gene, and accordingly an increased risk to atopic dermatitis, asthma, allergic rhinitis etc. It was found that the defect in filaggrin production leads to a lower than normal concentration of NMF in the stratum corneum of an individual, which can be detected by vibrational spectroscopy.
  • the method of the invention allows the distinction between a heterozygous carrier of a filaggrin mutation, which can result in a moderately decreased detectable NMF content in the stratum corneum, and a homozygous carrier of the filaggrin mutation, which may result in a substantially complete absence of detectable NMF in the stratum corneum.
  • a vibrational spectrum, or selected parts thereof, of the stratum corneum of the individual is measured.
  • the vibrational spectrum may be measured using any vibrational spectroscopy technique.
  • the preferred spectroscopic method is Raman spectroscopy.
  • Other spectroscopy methods include infrared spectroscopy, such as near-infrared spectroscopy, Fourier transform infrared (FT-IR) spectroscopy, or attenuated total reflection (ATR) infrared spectroscopy, for example as described by Bommannan et al. J. Invest. Dermatol. 1990, 95(4), 403-408.
  • the vibrational spectrum is a representation of the molecular composition of a sample.
  • the NMF content in the stratum corneum can be determined from the vibrational spectrum in any of the following ways.
  • the NMF content is determined as the intensity of the vibrational signal of NMF relative to the intensity of the vibrational signal of an internal reference.
  • a suitable internal reference is for instance the signal of keratin. Accordingly, the NMF content may be determined as the ratio of the NMF-signal intensity to the keratin-signal intensity.
  • suitable internal reference is for instance the signal of keratin.
  • the NMF content may be determined as the ratio of the NMF-signal intensity to the keratin-signal intensity.
  • other common constituents of the skin not belonging to the group of molecular compounds that together constitute the NMF, can be used as suitable internal reference.
  • such an internal reference may be the vibrational signal of a sample of stratum corneum tissue after removal of all or most of the molecular compounds that together constitute the NMF.
  • a method to extract NMF from a sample of stratum corneum has been described in Caspers et al. J. Invest. Dermatol. 2001, 116, 434-442.
  • Signal intensities can suitably be determined from the vibrational signal in one or more wavelength intervals, in which NMF signal contributions are dominant and one or more wavelengths intervals in which the internal reference signal contributions are dominant.
  • the NMF signal intensity may then be determined from an area A 1 under the curve in one or more wavelength intervals in which the signal contribution of NMF is dominant (see Figures 1 and 2, areas numbered 1 and 2).
  • signal intensities are measured in one or more wavelength intervals in which NMF signal contributions are dominant, in one or more wavelengths intervals in which the internal reference signal contributions are dominant, and in one ore more spectral intervals in which little or no Raman signal is anticipated and which may therefore serve to estimate background signal intensities.
  • the NMF content may then be determined from an area A3 under the curve of a dominant NMF signal and an area A 4 under the curve of the internal reference signal.
  • the areas under the curve may be determined from the measured signal intensities in the different wavelength intervals according to the following expressions, wherein I n is the measured signal intensity in spectral interval n, A n is the area under the curve in spectral interval n, x n is the central wavenumber of spectral interval n, y n is the average signal intensity in spectral interval n, and d n is the width of spectral interval n (see Figure 3).
  • Area A3 under the curve for NMF can be determined using
  • A, I, -diy x ⁇ y * - y ⁇ X * - ⁇ ⁇ (1)
  • the NMF content is determined from the intensity of the vibrational signal of NMF, relative to the intensity of the vibrational signal of an internal reference.
  • a suitable internal reference is for instance keratin.
  • the NMF content is determined by spectral fitting. From a reference set of vibrational spectra that comprise the vibrational spectrum of skin or most of the vibrational spectrum of skin, the contribution of each reference spectrum to the vibrational spectrum of skin is determined. The relative contributions may be determined by fitting the reference spectra or selected spectral regions of the reference spectra to the vibrational spectrum of skin or selected spectral regions of the vibrational spectrum of skin. The fit coefficients represent the relative contributions of each of the reference spectra. [Caspers et al. J. Invest.
  • one of the reference spectra is a spectrum of NMF.
  • one or more reference spectra are spectra of constituents of NMF.
  • the set of reference spectra may be collected in vitro from pure skin constituents, solutions of pure skin constituents and/or assemblies of pure skin constituents.
  • a particularly preferred skin constituent that may be used for a reference spectrum is keratin.
  • the NMF content is determined by calculation of the intensity of one or more peaks in the vibrational spectrum of NMF or in the spectra of constituents of NMF, and calculation of the intensity of one or more peaks in the spectrum of an internal reference.
  • a suitable internal reference is for instance keratin.
  • other common constituents of the stratum corneum, not belonging to the group of molecular compounds that together constitute the NMF can be used as suitable internal reference.
  • Vibrational spectra and more in particular Raman spectra, can be analysed automatically and in real-time on a personal computer, which is programmed to calculate the NMF content in the stratum corneum from a vibrational spectrum. This makes the result of the analysis instantly available.
  • the vibrational spectra are stored and analysed at a later time.
  • the NMF content is determined by recording vibrational spectra in vivo, directly on the skin.
  • the NMF content can also be determined by recording vibrational spectra ex vivo on a stratum corneum sample that has been taken from the individual.
  • the local NMF content is determined by measuring vibrational spectra as a function of the distance to the surface of the skin. This results in a so-called NMF depth profile.
  • the NMF content in the skin is determined by measuring vibrational spectra at a fixed and optimal distance from the skin surface at a given body location, preferably in the central part of the stratum corneum.
  • the vibrational spectra of the stratum corneum on the thenar can be measured at a point 1-70 ⁇ m beneath the skin surface, preferably at a point 2-50 ⁇ m beneath the skin surface, more preferably at a point 3-30 ⁇ m beneath the skin surface.
  • the vibrational spectra of the stratum corneum, on for example the volar aspect of the forearm can be measured 1-10 ⁇ m beneath the skin surface, preferably 2-8 ⁇ m, more preferably 3-6 ⁇ m beneath the skin surface.
  • the overall NMF content in the stratum corneum is determined as an average NMF content across the full thickness of the stratum corneum or across a specific depth range.
  • the NMF content can be measured at a number of different distances below the skin surface, for instance at three different distances below the skin.
  • the NMF content is measured at about 30, 40 and 50 ⁇ m beneath the skin surface.
  • the NMF content is measured at about 4, 6 and 8 ⁇ m beneath the skin surface.
  • the NMF content measured at different depths can then be averaged to yield a single NMF content value.
  • the overall NMF content in the stratum corneum is measured as an average NMF content across the full or partial thickness of the stratum corneum.
  • the Raman instrument can have a depth resolution which is equal in size, in the axial dimension, as the full or partial thickness of the stratum corneum.
  • a vibrational spectra can be measured at a fixed and optimal distance from the skin surface at a given body location, preferably in the central part of the stratum. As a result a vibrational spectrum of the full or partial thickness of the stratum corneum can be measured in a single measurement.
  • One or more vibrational spectra can be measured in the stratum corneum of an individual. It is preferred that more than one spectrum is measured, for instance at least 2 spectra, preferably at least 5 spectra, and more preferably at least 10 spectra. Measurements of the NMF content may be repeated several times (such as 2-10 times) on slightly different locations, in order to average out the lateral biological variation in the NMF content.
  • the slightly different locations can for instance be a translation over 0.05-1 mm, preferably 0.1-0.75 mm, more preferably 0.2-0.5 mm.
  • the vibrational spectra are recorded on the thenar of the individual.
  • Another preferred location to perform the vibrational spectra is the volar aspect of the forearm of the individual.
  • the vibrational spectra may be recorded on any other part of the body surface of the individual.
  • the vibrational spectra are measured by Raman spectroscopy.
  • an in vivo confocal Raman microspectrometer as described by Caspers et al. may be used to record the vibrational spectra.
  • Caspers et al. Biospectroscopy 1998, 4, 31-39 and Caspers et al. J. Invest. Dermatol. 2001, 116, 434-442 Another example of an in vivo confocal Raman microspectrometer is the model 3510 Skin Composition Analyzer (River Diagnostics, Rotterdam, The Netherlands).
  • a simple Raman spectrometer is suitable for carrying out the method of the invention.
  • the laser light is focused at a fixed distance from the skin surface.
  • this fixed distance can be at 1-70 ⁇ m below the skin surface, preferably 2-50 ⁇ m, more preferably 3-30 ⁇ m.
  • the fixed distance can be at 1-10 ⁇ m, preferably 2-8 ⁇ m, more preferably 3-6 ⁇ m. This eliminates the need for an accurate dynamic focussing device, which is part of commercially available confocal systems, such as the Model 3510 Skin Composition Analyzer (River Diagnostics).
  • the Raman spectrometer has a high spatial resolution.
  • a moderate or low spatial resolution can be of advantage, since it enables signal collection from e.g. a single relatively large part of the stratum corneum in one measurement.
  • simpler and less expensive optical components in the light delivery and the light detection path can be used.
  • a Raman spectrometer can be used, which detects several selected parts of the Raman spectrum with a low spectral resolution, and still provide sufficient information to distinguish between normal and aberrant NMF content.
  • the main signal contributions from NMF occur in the three spectral windows 800-900 cm 1 , 1280-1480 cm 1 and 1640-1660 cm 1 , see Figure 4.
  • the Raman signal of NMF is recorded in one or more of these spectral regions, and the Raman spectrum of the internal standard, see Figure 5, in a non- or partially overlapping spectral region.
  • a commercially available Raman skin analyser may be used. For example a Model 3510 Skin Composition Analyzer (River Diagnostics) may be used.
  • This system was designed for rapid, non-invasive analysis of the molecular composition of the skin.
  • the device enables measurement of Raman spectra of the skin at a range of depths below the skin surface, and thereby enables quantitative and semi-quantitative analysis of molecular concentrations or contents in the skin as a function of distance to the skin surface.
  • the method of the invention enables the determination whether a specific individual is unsuitable, or at least less suitable, for a certain profession (such as hair-dresser or cook) or activity.
  • the method of the invention further allows to differentiate between a homozygous and a heterozygous loss-of-function mutation in the filaggrin gene of an individual by classifying the loss-of-function mutation as a function of the natural moisturising factor content.
  • a moderately decreased detectable NMF content in the stratum corneum is an indication of a heterozygous carrier of a filaggrin mutation, while substantially complete absence of detectable NMF in the stratum corneum is an indication of a homozygous carrier of the filaggrin mutation.
  • the invention is directed to a method for treating an individual suffering from atopic dermatitis, comprising determining whether the individual has a potential presence of one or more loss-of-function mutation(s) in the gene encoding for filaggrin as described above, and adjusting the therapy based on the outcome of said determination.
  • the therapy can for instance be adjusted by directing it more specifically to skin barrier impairment and can include administering of oral antihistamines, topical emollients, topical doxepin, topical corticosteroids, topical hydrocortisones, topical immunomodulators, and/or ultraviolet light therapy.
  • the method of the invention is an attractive and relatively cheap screening method. Based on the results from this schreening it can be determined whether further (more expensive) screening or diagnosis is necessary.
  • Measurements were carried out on a panel of individuals, consisting of 7 individuals without known loss-of-function mutations in the filaggrin gene and 6 individuals with a known loss-of-function mutation, either R501X or 2282del4, in the fillagrin gene.
  • an in vivo confocal Raman microspectrometer Model 3510 Skin Composition Analyzer was used. The individual placed the skin region of interest on a fused silica window mounted in the measurement stage. Laser light was focused in the skin with a microscope objective located under the window. The distance of the laser focus to the skin surface was controlled by the instrument control software (RiverICon, River Diagnostics). After the start and end points and the incremental step size had been defined, the software automatically recorded a depth profile consisting of a series of Raman spectra recorded in the skin at a range of distances to the skin surface.
  • Raman measurements were conducted on the volar aspect of the forearm and on the thenar of the individuals. Laser light of 785 nm was focused in the skin and Raman spectra were recorded in the 400-1800 cm 1 spectral region, herein defined as the "fingerprint region".
  • the recorded depth range on the arm was 0 to 20 ⁇ m at 4 ⁇ m steps.
  • the recorded depth ranges on the thenar were 30 to 50 ⁇ m at 10 ⁇ m steps. Measurements on the arm and on the thenar were repeated 10 times for each individual in between which the precise measurement location was changed slightly with translations in the order of 50-500 ⁇ m.
  • the wavenumber axis of the spectra was calibrated using the internal calibration standards of the Model 3510 Skin Composition Analyzer and instrument control software RiverICon (River Diagnostics). This software was also used to correct for the wavenumber dependent signal detection efficiency of the instrument.
  • the analysis method used by the software is described by Caspers et al. in J. Invest. Dermatol. 2001, 116, 434-442.
  • the analysis method includes a classical least squares fitting step, in which a set of reference spectra of the major skin constituents is fitted to the Raman spectra of the arm or the palm, respectively.
  • the fit coefficients are divided by the fit coefficient for the spectrum of keratin, which is the dominant dry mass fraction in the stratum corneum.
  • This normalisation step corrects for variations in the absolute Raman intensity, which decreases with the distance of the laser focus position to the skin surface.
  • the result of the analysis method is a measure of the relative NMF content, expressed in arbitrary units as an NMF to keratin ratio. For each individual the average NMF content in the stratum corneum of the thenar was determined by calculating the numerical average of the relative NMF contents measured from 30-50 ⁇ m below the skin surface.
  • the average NMF content in the stratum corneum of the arm was determined from the relative NMF contents measured at 4 ⁇ m below the skin surface.
  • the invention allows, despite the large biological variations in NMF content that have been reported, designing measurement protocols such that individuals with a potential loss-of-function mutation in the filaggrin gene, which predisposes for certain skin conditions, can be reliably identified.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne un procédé de détermination non envahissante de la présence potentielle d'une ou de plusieurs mutations de perte de fonction du gène codant pour la filaggrine. Le procédé de l'invention comprend (i) l'obtention d'un spectre vibratoire à partir de la couche cornée (stratum corneum) de l'individu ; (ii) la détermination de la teneur en facteur hydratant naturel local du spectre vibratoire ; (iii) facultativement la répétition des étapes (i) et (ii) ; et (iv) la comparaison de la teneur en facteur hydratant naturel local de l'individu à une valeur de référence.
PCT/NL2007/050317 2007-06-28 2007-06-28 Procédé de détermination d'une mutation potentielle Ceased WO2009002149A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
PCT/NL2007/050317 WO2009002149A1 (fr) 2007-06-28 2007-06-28 Procédé de détermination d'une mutation potentielle
US12/666,311 US20100322860A1 (en) 2007-06-28 2008-06-25 Method for determination of a potential mutation
EP08766842.2A EP2175778B1 (fr) 2007-06-28 2008-06-25 Procédé permettant de déterminer une mutation potentielle
JP2010514662A JP5451607B2 (ja) 2007-06-28 2008-06-25 突然変異の可能性を判定する方法
PCT/NL2008/050419 WO2009002170A1 (fr) 2007-06-28 2008-06-25 Procédé permettant de déterminer une mutation potentielle
US15/661,273 US20170319070A1 (en) 2007-06-28 2017-07-27 Method for determination of a potential mutation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2007/050317 WO2009002149A1 (fr) 2007-06-28 2007-06-28 Procédé de détermination d'une mutation potentielle

Publications (1)

Publication Number Publication Date
WO2009002149A1 true WO2009002149A1 (fr) 2008-12-31

Family

ID=39135182

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2007/050317 Ceased WO2009002149A1 (fr) 2007-06-28 2007-06-28 Procédé de détermination d'une mutation potentielle

Country Status (1)

Country Link
WO (1) WO2009002149A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010114375A1 (fr) 2009-04-01 2010-10-07 River Diagnostics B.V. Procédé de détermination de mutations inconnues
CN106701906A (zh) * 2015-11-18 2017-05-24 深圳北京大学香港科技大学医学中心 一种快速判定丝聚蛋白基因c.3321delA突变的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030109774A1 (en) * 2001-01-18 2003-06-12 Lucassen Gerhardus Wihelmus Analysis of a composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030109774A1 (en) * 2001-01-18 2003-06-12 Lucassen Gerhardus Wihelmus Analysis of a composition

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CASPERS P J ET AL: "In Vivo Confocal Raman Microspectroscopy of the Skin: Noninvasive Determination of Molecular Concentration Profiles", JOURNAL OF INVESTIGATIVE DERMATOLOGY, NEW YORK, NY, US, vol. 116, no. 3, March 2001 (2001-03-01), pages 434 - 442, XP002220321, ISSN: 0022-202X *
CHRIT L ET AL: "In vivo chemical investigation of human skin using a confocal Raman fiber optic microprobe", J BIOMED OPT; JOURNAL OF BIOMEDICAL OPTICS JULY/AUGUST 2005, vol. 10, no. 4, July 2005 (2005-07-01), XP002471926 *
PALMER COLIN N A ET AL: "Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis", NATURE GENETICS, NEW YORK, NY, US, vol. 38, no. 4, April 2006 (2006-04-01), pages 441 - 446, XP002444720, ISSN: 1061-4036 *
RAWLINGS ANTHONY V ET AL: "Stratum corneum moisturization at the molecular level", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 103, no. 5, 1994, pages 731 - 740, XP002471925, ISSN: 0022-202X *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010114375A1 (fr) 2009-04-01 2010-10-07 River Diagnostics B.V. Procédé de détermination de mutations inconnues
WO2010114361A1 (fr) * 2009-04-01 2010-10-07 River Diagnostic B.V. Procédé de détermination d'une ou plusieurs mutations
CN106701906A (zh) * 2015-11-18 2017-05-24 深圳北京大学香港科技大学医学中心 一种快速判定丝聚蛋白基因c.3321delA突变的方法

Similar Documents

Publication Publication Date Title
Caspers et al. In vivo confocal Raman microspectroscopy of the skin: noninvasive determination of molecular concentration profiles
US20170319070A1 (en) Method for determination of a potential mutation
US7139598B2 (en) Determination of a measure of a glycation end-product or disease state using tissue fluorescence
Lieber et al. In vivo nonmelanoma skin cancer diagnosis using Raman microspectroscopy
US6501982B1 (en) System for the noninvasive estimation of relative age
US8238993B2 (en) Determination of a measure of a glycation end-product or disease state using tissue fluorescence lifetime
US20120078075A1 (en) Determination of a measure of a glycation end-product or disease state using tissue fluorescence in combination with one or more other tests
US20080269616A1 (en) Mir spectroscopy of tissue
EP2416708B1 (fr) Procédé de détermination d'une ou plusieurs mutations
AU2013224476B2 (en) Analytical method for common and specific characterization of skin carcinogenesis by FTIR microspectroscopy
Portaccio et al. Infrared microspectroscopy characterization of gingival crevicular fluid during orthodontic treatment
JP4329360B2 (ja) グルコース濃度の定量装置
Laing et al. Confocal Raman Spectroscopy as a tool to measure the prevention of skin penetration by a specifically designed topical medical device
Park et al. Feasibility study for diagnosis of stomach adenoma and cancer using IR spectroscopy
Sharma et al. Raman spectroscopy: incorporating the chemical dimension into dermatological diagnosis
US20110257492A1 (en) Method for determining the state of a skin disorder using near infrared (nir) spectroscopy
Eikje et al. Identification and characterization of skin biomolecules for drug targeting and monitoring by vibrational spectroscopy
JP2004321325A (ja) 血糖値の定量方法
Li et al. Raman spectroscopy for molecular diagnosis of psoriatic nails with SEM validation
González Noninvasive detection of filaggrin molecules by raman spectroscopy
Chandra Sekhar et al. Discrimination of periodontal diseases using diffuse reflectance spectral intensity ratios
Hattery et al. Differential oblique angle spectroscopy of the oral epithelium
Camerlingo et al. Wavelet data analysis of micro-Raman spectra for follow-up monitoring in oral pathologies
Lieber et al. IN-VIVO NONMELANOMA SKIN CANCER DETECTION USING CONFOCAL RAMAN SPECTROSCOPY

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07747539

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07747539

Country of ref document: EP

Kind code of ref document: A1